Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fentanyl iontophoretic - ALZA Corporation

Drug Profile

Fentanyl iontophoretic - ALZA Corporation

Alternative Names: E-TRANS fentanyl; Fentanyl HCI; Fentanyl iontophoretic transdermal system; Fentanyl transdermal - ALZA Corporation; IONSYS; SyB P 1501

Latest Information Update: 23 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALZA Corporation
  • Developer The Medicines Company
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Postoperative pain

Most Recent Events

  • 09 Feb 2018 SymBio Pharmaceuticals terminates a phase III trial for Postoperative pain due to the announcement for completion of the termination of development of SyB P-1501 in Japan (Transdermal) (NCT03005899)
  • 09 Feb 2018 Discontinued - Phase-III for Postoperative pain in Japan (Transdermal)
  • 30 Nov 2017 The Medicines Company terminates its license with SymBio Pharmaceuticals for Fentanyl iontophoretic in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top